Chondrosarcoma Therapeutic Pipeline: 2025 Development Landscape and Market 

DelveInsight's comprehensive 2025 analysis of the Chondrosarcoma pipeline delivers extensive intelligence on over 15 companies and more than 15 investigational therapies currently advancing through development. This detailed examination encompasses drug candidate profiles across all developmental phases, from preclinical research through clinical trials. The assessment evaluates therapeutic candidates by product classification, developmental phase, administration method, and molecular structure, while also documenting discontinued Chondrosarcoma programs in this therapeutic area.

Explore our latest breakthroughs in Chondrosarcoma Research. Learn more about our innovative pipeline today! @ Chondrosarcoma Pipeline Outlook

Key Highlights from the Pipeline Analysis

• On 18 November 2025, the Italian Sarcoma Group initiated a phase II clinical investigation to examine trabectedin's therapeutic activity in patients aged ≥16 years presenting with progressive, advanced disease (locally advanced or metastatic).

• On 12 November 2025, Servier Bio-Innovation LLC revealed plans for a phase 3 investigation of Ivosidenib in participants ≥18 years of age diagnosed with locally advanced or metastatic conventional chondrosarcoma harboring an IDH1 mutation, either treatment-naïve or previously treated with 1 systemic treatment regimen.

• The current landscape shows a dynamic field with over 15 companies actively advancing more than 15 therapeutic candidates for chondrosarcoma management.

• Key pharmaceutical developers include PharmaMar, Inhibrx, Shanghai Junshi Bioscience Co. Ltd., Hutchmed, Atlanthera and others.

• Notable investigational therapies comprise Pazopanib, Trabectedin, INBRX-109, AG-120, IPI-926, Perifosine, Loperamide, Allopurinol, Enasidenib and additional candidates.

Stay informed about the cutting-edge advancements in Chondrosarcoma treatments. Download for updates and be a part of the revolution @ Chondrosarcoma Clinical Trials Assessment

Understanding Chondrosarcoma

Chondrosarcoma (CS) represents a category of bone malignancies composed of cells that produce excessive cartilage tissue. Cartilage constitutes the specialized, gristly connective tissue present in adults and serves as the foundational tissue from which most bones originate. Cartilage performs a critical function in developmental processes. Multiple distinct cartilage types exist throughout the body. Chondrosarcoma predominantly impacts the cartilage cells within the femur (thighbone), arm, pelvis, or knee regions. Although occurring less frequently, other anatomical sites (such as the ribs) may be involved. Chondrosarcomas are malignant cartilaginous neoplasms exhibiting diverse morphological characteristics and clinical presentation. They represent approximately 20% of all primary malignant bone tumors. These malignancies typically originate in the pelvis or long bones.

Featured Investigational Therapies

Trabectedin: PharmaMar Trabectedin, alternatively designated as ecteinascidin 743 or ET-743, or commercially marketed as Yondelis® where approved, represents a synthetic derivative obtained from the colonial sea squirt Ecteinascidia turbinata. Trabectedin suppresses active transcription of protein-encoding genes by binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, consequently inducing double-stranded DNA breaks and apoptotic cell death. Trabectedin (Yondelis) is an anti-neoplastic agent of marine origin discovered in the Caribbean tunicate, Ecteinascidia turbinata. The compound is formulated as lyophilized powder for solution preparation for injection via intravenous administration. Yondelis is indicated for treating adult patients with advanced soft tissue sarcoma following anthracycline and ifosfamide failure, or for those unsuitable to receive these agents. This therapeutic candidate is presently undergoing Phase II clinical assessment for mesenchymal chondrosarcoma treatment.

INBRX-109: Inhibrx INBRX-109 represents a precisely engineered tetravalent single domain antibody (sdAb)-based therapeutic candidate that agonizes death receptor 5 (DR5) to trigger tumor-selective programmed cell death. INBRX-109, a tetravalent DR5 agonistic antibody, is designed to exploit tumor-preferential direct cell death induction through DR5 activation across numerous cancer types. With its tetravalent structure, it demonstrates the capacity to potently activate DR5 through efficient receptor clustering, inducing cellular death, while the sdAb platform simultaneously eliminates recognition by pre-existing anti-drug antibodies (ADAs) to reduce hyper-clustering potential. In preclinical investigations, INBRX-109 demonstrated antitumor activity in vitro and in patient-derived xenograft models, exhibiting minimal hepatotoxic effects. This compound is currently advancing through Phase II clinical evaluation for chondrosarcoma treatment.

JS001sc: Shanghai Junshi Bioscience Co., Ltd. JS001sc injection represents a subcutaneous injection formulation developed by Junshi Biosciences based on the marketed product toripalimab. JS001sc targets PD-1, demonstrates high-affinity binding to PD-1, and selectively blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby activating T lymphocytes and enhancing lymphocyte proliferation and cytokine secretion. Preclinical in vivo pharmacodynamic studies reveal that JS001sc exhibits substantial anti-tumor efficacy in animal models via subcutaneous administration. At specific dosage levels, the anti-neoplastic effect of subcutaneously administered JS001sc is comparable to intravenously administered toripalimab, showing no significant difference. Additionally, animals demonstrate favorable tolerance to JS001sc. To date, JS001sc has obtained clinical trial authorization from the NMPA. This candidate is currently in Phase I clinical evaluation for chondrosarcoma treatment.

HMPL-306: Hutchmed HMPL-306 is an investigational compound under development by Hutchmed. HMPL-306 represents an investigational novel selective small molecule dual inhibitor of isocitrate dehydrogenase (IDH) 1 and 2 mutations. IDH1 and IDH2 mutations have been identified as oncogenic drivers in certain hematological malignancies, gliomas and solid tumors, particularly among acute myeloid leukemia patients. Cytoplasmic mutant IDH1 and mitochondrial mutant IDH2 have demonstrated the capacity to convert to the alternate form when targeted by an IDH1 mutant-specific inhibitor or IDH2 mutant-specific inhibitor alone. Cancer patients harboring either IDH mutation have demonstrated the development of resistance to IDH1 or IDH2-targeted therapies through isoform switching mechanisms. This compound is currently advancing through Phase I clinical evaluation for chondrosarcoma treatment.

Learn more about Chondrosarcoma Drugs opportunities in our groundbreaking Chondrosarcoma research and development projects @ Chondrosarcoma Unmet Needs

Report Coverage and Analysis

This comprehensive pipeline report delivers intelligence on:

• Detailed profiles of pharmaceutical companies developing chondrosarcoma therapeutics, including aggregate therapy portfolios from each organization.

• Assessment of therapeutic candidates classified by early-stage, mid-stage, and late-stage development phases.

• Active and inactive (dormant or discontinued) pipeline programs across participating companies.

• Categorization of investigational drugs by developmental stage, delivery route, target receptor, treatment approach (monotherapy or combination), mechanism of action, and molecular classification.

• In-depth examination of partnerships (industry collaborations and academic alliances), licensing arrangements, and funding details relevant to future market advancement.

Featured Companies

PharmaMar, Inhibrx, Shanghai Junshi Bioscience Co. Ltd., Hutchmed, Atlanthera and others.

Route of Administration Categories

Pipeline products are organized by delivery method:

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Molecular Type Classifications

Investigational products are categorized by molecular structure:

• Oligonucleotide

• Peptide

• Small molecule

Discover the latest advancements in Chondrosarcoma treatment by visiting our website. Stay informed about how we're transforming the future of Neurology @ Chondrosarcoma Market Drivers and Barriers, and Future Perspectives

Report Scope

• Geographic Coverage: Global

• Featured Companies: PharmaMar, Inhibrx, Shanghai Junshi Bioscience Co. Ltd., Hutchmed, Atlanthera and others

• Pipeline Therapies: Pazopanib, Trabectedin, INBRX-109, AG-120, IPI-926, Perifosine, Loperamide, Allopurinol, Enasidenib and others

• Product Type Assessment: Monotherapy, Combination therapy, Mono/Combination approaches

• Clinical Stage Assessment: Discovery, Preclinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Chondrosarcoma Pipeline on our website, @ Chondrosarcoma Emerging Drugs and Companies

Report Structure

1. Introduction

2. Executive Summary

3. Chondrosarcoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Chondrosarcoma– DelveInsight's Analytical Perspective

7. Mid Stage Products (Phase II)

8. Trabectedin: PharmaMar

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase I/II)

11. Seclidemstat: Salarius Pharmaceuticals, LLC

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. JS001sc: Shanghai Junshi Bioscience Co., Ltd.

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Ifosfamide: Atlanthera

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Chondrosarcoma Key Companies

21. Chondrosarcoma Key Products

22. Chondrosarcoma- Unmet Needs

23. Chondrosarcoma- Market Drivers and Barriers

24. Chondrosarcoma- Future Perspectives and Conclusion

25. Chondrosarcoma Analyst Views

26. Chondrosarcoma Key Companies

27. Appendix

About DelveInsight

DelveInsight operates as a premier healthcare-focused market research and consulting organization, delivering high-caliber market intelligence and analytical insights that empower informed business decision-making. Supported by seasoned industry specialists and comprehensive expertise in life sciences and healthcare domains, the firm provides tailored research solutions and strategic insights to a global client base. Engage with our team to access premium-quality, precise, and current intelligence that positions you ahead of market developments.

Contact Us

Kanishk

kkumar@delveinsight.com